LOGIN  |  REGISTER
Amneal Pharmaceuticals

Xtant Medical to Issue First Quarter 2023 Financial Results on May 4, 2023

April 27, 2023 | Last Trade: US$0.85 0.01 -1.61

BELGRADE, Mont., April 27, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, before the open of the financial markets on Thursday, May 4, 2023.

Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, May 4 at 9:00 AM ET to review results.

Conference Details
Conference Call Date: Thursday, May 4, 2023 - 9:00 AM ET
Conference dial-in: 877-407-6184
International dial-in: 201-389-0877
Conference Call Name: Xtant Medical Q1 2023 Financial Results
Webcast Registration: Click Here

Following the live call, a replay will be available on the Company’s website, www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Investor Relations Contact

David Carey
Lazar FINN Partners
Ph: 212-867-1762
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB